Weekly Stock Watch 21 Nov 2026: 8 Growth Stocks After Q2 FY27

Weekly stock watch for 21 Nov 2026: 8 Indian stocks with upcoming growth triggers after Q2 FY27 results, each screened on market cap and growth.

These stocks cleared our market-cap and growth checks this week, and each has at least one upcoming growth or re-rating trigger named in its latest company filings.

PANACHE (PANACHE): growth triggers and H1 FY27 outlook

- Current price: Rs 836.00 - Market cap: Rs 1339cr

Panache Digilife has more than doubled its revenue in H1FY27 to INR 180 crore while expanding EBITDA margins by over 300 basis points year-on-year to 9.6%, as operating leverage and a richer mix of design-led products — where the company owns the IP and earns 5–20%+ margins versus 3–7% on pure contract work — push profitability well beyond assembly-era levels. The company secured a significant 36-month telecom services contract and retains roughly 40% spare capacity at its Bhiwandi facility, meaning near-term order growth can be absorbed without fresh capital expenditure.

As one of Intel's oldest ODM partners in India — a designation that grants priority chip allocation when global supplies tighten — Panache is structurally placed to capture demand from the enterprise AI hardware refresh cycle driven by Windows 10's end-of-life and rising cloud AI costs. A newly established Hong Kong subsidiary broadens the addressable market into Asia, and management has explicitly flagged second-half FY27 as seasonally stronger, adding near-term earnings visibility to a business that has already delivered a roughly 5x jump in quarterly PAT year-on-year.

Management: "Our relationship with Intel goes for more than two decades. We are one of the oldest Intel partners in India and we are an ODM recognized under the Intel ecosystem." — MD Amit Rambhia

Upcoming growth and re-rating triggers

- Margin expansion: Raising DLM share from 40% toward majority can lift blended EBITDA margins well above 9.6% (DLM earns 5–20%+ vs CLM 3–7%) - Order book execution: 36-month telecom services contract via Panache Newage starts flowing revenue incrementally each quarter — multi-year recurring contribution - Operating leverage: ~40% spare capacity at existing Bhiwandi plant means next leg of revenue growth adds no new fixed costs, directly widening margins - New product / new market: Windows 10 end-of-life forces enterprise AI PC refresh; Panache's AI edge devices are directly positioned to capture this upgrade wave - Recent development: Hong Kong subsidiary Quantron is live, foreign nationals hired, Phase 1 targeting Asian markets — opens first-ever international revenue stream

Honasa Consumer (HONASA): growth triggers and Q2 FY27 outlook

- Current price: Rs 525.00 - Market cap: Rs 17143cr - Individual/HNI bulk-or-block BUY in last 3mo: ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED

Honasa Consumer delivered its strongest quarterly performance since listing in Q2FY27, with net sales up 36% year-on-year driven primarily by volume (31.3% unit volume growth) and PAT up ~90% year-on-year as EBITDA margins expanded to 12.7% — roughly double the prior-year level — on a structurally improving channel mix and operating leverage. The company's deliberate shift from pure e-commerce toward offline and quick-commerce channels is reducing platform commissions, while focus categories (face wash, sunscreen, shampoo, moisturizers) now contribute over 80% of revenue and grew 40%+ year-on-year.

Mamaearth gained 140 basis points of Nielsen face wash market share and The Derma Co. reached 65,000 offline outlets within just four quarters of an offline push, indicating brand momentum is broadening across channels rather than concentrating in one. At only ~5% penetration of an estimated ₹50,000 crore addressable market and a medium-term EBITDA margin target of 15% — with H1FY27 already tracking near 13.5% — institutional investors including ICICI Prudential Life Insurance have been adding exposure in recent months.

Management: "Q2 FY2027 is the highest growth quarter since we have gone public in the last 12 quarters." — Varun Alagh, CEO

Upcoming growth and re-rating triggers

- Margin expansion: H1FY27 EBITDA already ~13.5%; management guidance of 150-200 bps/year appears intentionally conservative; 15% target over 4 years. - Operating leverage: 36% revenue growth (31% volume-led) spreading fixed costs further; 110-140 bps EBITDA unlocked from operating leverage in Q2FY27 alone. - New store openings: The Derma Co. hit 65,000 offline outlets in just 4 quarters of focus with 1.2% face wash share — offline ramp still in early innings. - New product / new market: BBlunt care category (shampoo/conditioner) relaunch planned; hair color already 100%+ post-relaunch — care relaunch adds a new growth leg. - Recent development: Honasa confirmed exploring a second portfolio brand to enter hair color category — undisclosed strategic move; announcement on launch pending.

Asahi India Glass (ASAHIINDIA): growth triggers and Q2 FY27 outlook

- Current price: Rs 1164.00 - Market cap: Rs 29663cr

Asahi India Glass (AIS) just posted its best-ever quarter — Q2FY27 standalone revenue up 36.2% YoY and net profit up ~260% YoY to ₹171 Cr — led by a dramatic turnaround in Float Glass, where EBIT surged ~247% YoY to ₹137 Cr as the F2 furnace ran at full capacity versus a cold-repair period a year ago. EBITDA margins expanded roughly 500 bps YoY to ~22%, while finance costs fell 25.5% YoY, a sign that the company's deleveraging is now mechanically amplifying bottom-line gains.

AIS commands ~80% of India's passenger vehicle glass market and is simultaneously building out on the architectural side — commissioning Phase III tempered operations at Patan and new laminated capacity at Chennai within the same quarter. With H1FY27 PAT already at ₹316–322 Cr versus ₹101–113 Cr in H1FY26, the profit recovery is broad-based and the heavy capex cycle appears to be tapering, meaning incremental cash generation should improve from here.

Upcoming growth and re-rating triggers

- Operating leverage: Patan Phase III tempered & Chennai laminated just commissioned; current ramp-up drag will flip to margin recovery as utilisation scales - Other re-rating trigger: Capex collapsed from Rs.631 Cr (FY26) to Rs.174 Cr (H1FY27); free-cash-flow surge will accelerate debt paydown and trigger re-rating - Order book execution: 12 new OEM car models stabilised in Q2FY27; additional model launches guided for coming quarters, adding incremental automotive glass volume - Capacity expansion: Rs.348 Cr of CWIP still being completed; winding-down projects will add commissioned revenue-generating capacity in near term - Margin expansion: Finance costs already down 25.5% YoY to Rs.43 Cr; continued deleveraging will keep compressing interest burden and lifting PAT margins

Indo Count Industries (ICIL): growth triggers and Q2 FY27 outlook

- Current price: Rs 580.00 - Market cap: Rs 11492cr

Indo Count Industries (ICIL) has nearly tripled its profits year-on-year as its deliberate shift away from commodity bed-linen exports — into US-manufactured utility bedding and owned/licensed brands like Wamsutta and Tommy Hilfiger — drives a meaningful mix upgrade toward higher-margin revenue. Q2 FY27 was the company's highest-ever quarterly performance, with consolidated EBITDA margin expanding 380 basis points to 15.3% and net debt falling to its lowest-ever level at just 0.2x equity, leaving the balance sheet in its strongest shape in years. All three US utility bedding plants are now running above 65% utilization, and management expects full capacity by CY28 — with new businesses currently at low-double-digit EBITDA margins converging toward the 15% core business level, there is a visible multi-quarter tailwind baked into the numbers that doesn't depend on further revenue acceleration.

Management has reaffirmed a revenue doubling target from ₹4,000 crore to ₹8,000 crore by CY28, and crucially, no incremental growth capex is required to reach it, meaning the earnings ramp should convert more directly into free cash flow. The India-UK Free Trade Agreement, implemented in July 2026, opens a new geographic leg to the growth story as UK and EU customer inquiries have already increased materially.

Management: "Continuing with the Q1 momentum, we have delivered our highest-ever quarterly performance in Q2." — Mohit Jain, MD

Upcoming growth and re-rating triggers

- Operating leverage: New biz EBITDA margins rising from ~11-12% to 15% as US plants ramp to full utilization by CY28 — multi-quarter margin tailwind for blended margins. - Other re-rating trigger: Revenue to double from ₹4,000 Cr to ₹8,000 Cr by CY28 with zero incremental growth capex needed — pure asset-light scale-up re-rating story. - New product / new market: Wamsutta moved from DTC-only to broad US retail in Q2 FY27 and scaling through H2 FY27; branded business targeting $100 million by CY28. - Recent development: UK FTA implemented July 2026; inquiries from UK/EU customers already rising but volume conversion to firm orders not yet in the numbers. - New product / new market: EU FTA still pending; once live, expected to unlock incremental EU retail demand and shift the US/non-US revenue mix from 70/30 toward 60/40.

ALICON (ALICON): growth triggers and Q2 FY27 outlook

- Current price: Rs 1076.00 - Market cap: Rs 1766cr

Alicon Castalloy posted revenue growth of ~60% YoY and PAT growth of ~91% YoY, with Q2 FY27 marking the highest-ever single quarter in the company's history at Rs. 652 Cr in total income. The core story is a structural mix shift: 90% of all new business won in the last six months falls in the high-value-added, precision-machined category, and the company's commercial-vehicle cylinder head market share surged from 13% to 23% in just one year — signalling genuine competitive gains rather than just sector tailwind.

Alicon also holds a near-monopoly on hybrid vehicle cylinder heads in India and has a JLR EV program ramping to consumer sales by Q4 FY27, giving it meaningful exposure to India's EV and hybrid transition without the binary risk of a pure-play. A new 12,000 MT/yr Pune plant begins mass manufacturing in April 2027, and management is guiding for approximately one percentage point of annual EBITDA margin improvement from FY27 onward, with an alloy-adjusted margin target of 14–15% by FY30 versus ~12.1% today.

Management: "We are seeing higher customer offtake, a richer product mix, and a growing contribution from the new programs." — Sumit Bhatnagar, Group CEO

Upcoming growth and re-rating triggers

- Capacity expansion: New 12,000 MT/yr Pune plant fully booked by customers; mass manufacturing from April 2027, adding Rs. 120-150 Cr first-year revenue. - Recent order win: New major hybrid cylinder head program win to double hybrid revenues; Alicon holds ~100% share of India's hybrid cylinder head market. - New product / new market: First non-auto data-centre casting (Danfoss Turbocor-type) goes to SOP March 2027; Rs. 15-20 Cr FY28 target with more orders and Mexico location expected. - Operating leverage: 30 new SOPs over next 12 months drive ~1 ppt/yr EBITDA margin improvement; alloy-adj margin guided from 12.1% now to 14-15% by FY30.

Navin Fluorine International (NAVINFLUOR): growth triggers and Q2 FY27 outlook

- Current price: Rs 10077.00 - Market cap: Rs 51710cr

Navin Fluorine's Q2FY27 results show 31% revenue growth alongside a 53% jump in PAT — but the more structurally interesting signal is that margins are expanding at the same time, with H1FY27 EBITDA reaching 34.2%, up 367 basis points year-on-year. This margin expansion is not cyclical: it stems from a business mix increasingly tilted toward long-duration contracted revenue, anchored by the Honeywell/Solstice HFO supply agreement now extended through December 2032 and carrying an additional ~USD 180 million in revenue potential on the same existing asset base.

All three verticals are growing together, with Specialty Chemicals hitting its long-guided INR ~350 Cr quarterly run rate and the CDMO business approaching a USD 100 million annual order book backed by a dedicated cGMP facility producing the prostate cancer drug darolutamide for Fermion. NFIL's proprietary fluorine chemistry expertise, freshly commissioned backward integration into anhydrous HF, and an emerging Advanced Materials pipeline targeting semiconductors and defense give it multiple organic growth levers that are genuinely difficult for new entrants to replicate.

Management: "CDMO at 'striking distance' of USD 100 million order book target for FY27; cGMP-4 Phase 1 and Phase 2 combined peak revenue potential of INR 900–1,000 Cr by FY28/FY29."

Upcoming growth and re-rating triggers

- Capacity expansion: R32 HFC expansion commissioning Q3FY27 with partial ramp in Q3 and full ramp in Q4FY27, adding near-term HPP volumes. - Recent development: MPP Dahej debottlenecking commissioned Sep 2026 but contribution not yet in Q2 numbers; growth hits P&L from Q3FY27 onwards. - New product / new market: Chemours immersion-cooling fluid plant targeting Q3FY27 commissioning with purchase orders already in hand; opens data-center vertical. - Recent development: CDMO molecule approved in China and on FDA fast-track in US; darolutamide label expansion — both expand CDMO order book toward USD 100M target.

Alembic Pharmaceuticals (APLLTD): growth triggers and latest results outlook

- Current price: Rs 1041.00 - Market cap: Rs 20461cr

Alembic Pharmaceuticals has delivered a sharp acceleration in profitability, with revenue up 33% and PAT more than doubling year-on-year as EBITDA margins expanded 520 basis points to 22.2% — driven by operating leverage, a favorable product mix shift, and disciplined R&D spending held steady at 8% of revenue. The heavy multi-year capex cycle is now complete, meaning incremental revenue will increasingly flow through an already-built manufacturing base, improving asset turns without fresh greenfield spending. Beyond the near-term bosutinib exclusivity tailwind in U.S. generics (which winds down in November 2026), the base U.S. portfolio grew 23% on its own, signaling genuine volume momentum that management has built into a raised full-year revenue guidance of 20–25% growth.

The recently expanded DifGen collaboration adds 20-plus complex generic products — transdermal patches, injectables, ophthalmics — addressing a roughly $5 billion U.S. reference market, with contributions expected from FY28, providing a credible next chapter of growth beyond base generics. Net debt remains below one times full-year EBITDA, leaving the balance sheet in reasonable shape to absorb the ongoing U.S. branded build-out while funding the pipeline.

Management: "The second quarter builds decisively on the momentum of our first quarter and marks an important step up in the quality of our performance." — MD Pranav Amin

Upcoming growth and re-rating triggers

- Order book execution: 30+ U.S. generic launches planned over next 18 months, ~25% first-to-file or shared day-1 exclusivities — high-value revenue windows ahead. - Operating leverage: Major capex cycle complete; incremental revenue now flows over fixed asset base, driving asset turns and margin expansion beyond 520bps already achieved. - Recent development: FY27 revenue growth guidance raised to 20–25% YoY from prior mid-teens; U.S. guided at 40% YoY — upgrade not yet fully reflected in consensus. - Other re-rating trigger: India Human Health targeting double-digit market-level growth in Q3/Q4 FY27 via stronger metro presence and chronic/specialty mix shift.

Emcure Pharmaceuticals (EMCURE): growth triggers and latest results outlook

- Current price: Rs 2338.00 - Market cap: Rs 44351cr

Emcure Pharmaceuticals delivered 32% revenue growth and more than doubled its PAT year-on-year, while EBITDA margins expanded 100 basis points to 20.4% — driven by operating leverage as SG&A and employee cost growth consistently trailed revenue. The international business is at a structural inflection: liposomal amphotericin B, a technically complex antifungal injection where Emcure is one of a handful of qualified global suppliers, is actively scaling across Europe with roughly 20 more country approvals still in the pipeline, and the high-growth RoW segment has already rebalanced from 67% lower-margin ARVs in Q1 to a 50/50 split with higher-value complex injectables by Q2.

Management has responded by raising full-year FY27 revenue growth guidance to above 20% and upgrading EBITDA margin improvement to the upper end of their 75–100 basis point range. Three mutual fund buy deals in the past three months add institutional conviction, and with the domestic business accelerating organically and the Zuventus field-force stabilising, the second half looks positioned to sustain momentum.

Management: "The foundation gives us confidence that the momentum will continue in the second half of FY27 and to raise our full year FY27 revenue growth outlook." — Satish Mehta, CMD

Upcoming growth and re-rating triggers

- New product / new market: Liposomal amphotericin B has only ~50% of European geographies approved; ~20 countries still pending, with batches already in production for new RoW markets. - New product / new market: Treprostinil launch in Europe flagged as next major product after amphotericin B, expected to contribute significantly within 12 months; limited competition, high value and margin. - New product / new market: Semaglutide biosimilar filing in Canada expected before March 2027; supply partner Dr. Reddy's targeting November 2026 launch — a high-value obesity/diabetes market entry. - Operating leverage: Management explicitly guided SG&A to grow slower than revenue; employee costs +13% vs revenue +24% in Q2; FY27 EBITDA margin guidance upgraded to upper end of 75–100bps band.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.